Section ATop Stories
The three that actually matter this morning.
Hepatitis B "functional cure" moves from aspiration to achievable
New 72-week data on the antisense drug bepirovirsen show roughly 20% of treated patients reached a functional cure (sustained loss of surface antigen off-treatment) versus none on placebo — the strongest signal yet that finite-duration HBV therapy is real, not theoretical.
Why it matters to you: You admit plenty of older patients with chronic HBV riding along in the background — cirrhosis workups, immunosuppression flares, reactivation risk when you start steroids or chemo-adjacent regimens. A curative-intent pathway changes how hepatology will frame these consults over the next few years.
Talking point: Worth a quick note to your ID/hepatology colleagues — reactivation screening before immunosuppression only gets more important if cure is on the table.
Cuba: third nationwide blackout of the year — UN warns of humanitarian emergency
Update: After Monday's total grid collapse (covered yesterday), power is trickling back but slowly — UNE was serving only ~1% of Havana's demand by late afternoon. Fuel has been drying up since January; officials say tens of thousands of surgeries have been postponed, and the UN is now openly warning of a humanitarian emergency around food, water, and medicine.
Why it matters to you: Beyond the family connection — this is a public-health story now, not just an energy one. Canceled surgeries and medicine shortages at national scale are the kind of thing that ripples into diaspora health and, eventually, Florida clinics.
Note: Reported straight from mainstream wires (Al Jazeera, CNN, CBS) — no exile-press framing.
Federal audit: nine years after Maria, only ~25% of Puerto Rico's grid money has landed
A federal audit released July 1 found that of roughly $14B obligated for Puerto Rico's power grid after Hurricane Maria, only about a quarter has actually been disbursed — of $11B obligated by FEMA alone, ~$2.7B has gone out, mostly for equipment and design costs. This lands as the 2026 hurricane season (forecast near-to-below average) gets underway.
Why it matters to you: Same structural fragility that makes Cuba's grid a health story makes PR's a health story — an island still one bad storm away from the ICU-on-generators scenario, with the rebuild money stuck in the pipe.
Talking point: A concrete data point for anyone who assumes the post-Maria recovery is "done."
Section BThe Debate
One live argument, both sides steelmanned. No verdict.
Should nurse practitioners be granted full, independent practice authority?
Why it's live: roughly 30 states plus D.C. now grant some form of full practice authority (up from 22 in 2020), New York's latest expansion carries a July deadline, and the AMA used its 2026 State Advocacy Summit and a fresh Florida practice-pattern study to push back hard — committing $1M/year to fight scope bills. The two camps are arguing past each other in real time.
For — expand it
Access is the whole game. With ~30 states plus D.C. already granting full practice authority and no measurable drop in patient outcomes, the American Association of Nurse Practitioners (president Valerie Fuller) argues restrictive supervision rules are an artificial brake on care — especially in rural and underserved areas where FPA is linked to more primary-care utilization and fewer avoidable ER visits. Physician shortages aren't hypothetical; NPs are already filling the gap safely.
AANP — State Practice Environment
Against — keep physician oversight
Training depth and scope discipline matter. The AMA counters that physicians log 10,000–16,000 clinical hours in residency versus 500–720 for NP graduate training, and warns that independent authority correlates with more diagnostic testing and higher antibiotic/opioid prescribing. A February 2026 study found more than half of Florida's autonomous NPs practicing outside primary care — in med-spas and even cardiology — undercutting the "we're solving the primary-care shortage" case.
AMA — Why expanding APRN scope is a bad idea
Where it might land: this moves state by state, not federally — watch the New York rollout and whichever legislatures pick it up next session. No single decision point ends it.